The ERA trial: Findings and implications for the future

Climacteric

Volumn 3, Issue 4, 2000, Pages 227-232

  Nair, G V ^a   Herrington, D M ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEDROXYPROGESTERONE ACETATE; PLACEBO; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TRIACYLGLYCEROL;

ANGIOCARDIOGRAPHY; ARTERY DIAMETER; BREAST CANCER; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY OBSTRUCTION; CURETTAGE; EDITORIAL; ENDOMETRIUM HYPERPLASIA; ESTROGEN THERAPY; FOLLOW UP; FRACTURE; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; PATIENT COMPLIANCE; POSTMENOPAUSE; PRIORITY JOURNAL;

EID: 0034470103     PISSN: 13697137     EISSN: None     Source Type: Journal    
DOI: 10.1080/13697130008500132     Document Type: Editorial

References (23)

1. Hormone therapy to prevent disease and prolong life in postmenopausal women
2. Prospective study of exogenous hormones and risk of pulmonary embolism in women
3. The protective effects of estrogen on the cardiovascular system
4. How do we explain the clinical benefits of estrogen? From bedside to bench
5. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
6. Cardioprotection for the postmenopausal women: HERS results and their implications
7. The HERS trial results: Paradigms lost?
8. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis
9. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women
10. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women
11. Hormone replacement therapy and increased plasma concentration of C-reactive protein
12. Effect of postmenopausal hormones on inflammation-sensitive proteins. The Postmenopausal Estrogen/Progestin Interventions (PEPI) study
13. Hormone replacement therapy, inflammation, and hemostasis in elderly women
14. Long-term effects of combined hormone replacement therapy on markers of endothelial function and inflammatory activity in healthy postmenopausal women
15. The direct anti-atherogenic effect of estrogen is present, absent, or reversed, depending on the state of the arterial endothelium. A time course study in cholesterol-clamped rabbits
16. Inhibition of coronary artery atherosclerosis by 17-beta estradiol in ovariectomized monkeys. Lack of an effect of added progesterone
17. Postmenopausal hormone replacement therapy prevents central distribution of body fat after menopause
18. Regression of atherosclerosis in female monkeys
19. Effect of 17-beta estradiol on pre-existing atherosclerotic lesions: Role of the endothelium
20. Oral contraceptives and cardiovascular disease
21. First-time use of newer oral contraceptives and the risk of venous thromboembolism
22. Increased risk of venous thrombosis in oral contraceptive users who are carriers of the Factor V Leiden mutation
23. In search of optimal long-term female hormone replacement: The potential of selective estrogen receptor modulators